Grifols invites you to join this satellite symposium at the 7th Congress of the European Academy of Neurology (EAN 2021) entitled “AMBAR: Plasma Exchange plus albumin replacement as an innovative treatment for Alzheimer’s disease”.

Research into Alzheimer’s disease (AD) at Grifols began in 2004 with a small clinical trial on the potential of plasma exchange with albumin to slow the progression of the disease in the treatment of patients in mild and moderate stages. More than a decade later, we are pleased to present the findings of AMBAR, the latest study in the program. The complete efficacy and safety results along with the scientific rationale supporting the medical procedure will be discussed.

Satellite Symposium at the 7th EAN Congress

AMBAR
Plasma Exchange plus albumin replacement as an innovative treatment for Alzheimer’s disease

Monday, June 21st, 2021
12.15h - 13.15h
Room Amsterdam
Chair: Mercè Boada, M.D., Ph.D. Fundació ACE, Universitat Internacional de Catalunya, Barcelona, Spain

5 min Introduction to AMBAR
Mercè Boada, M.D., Ph.D.

10 min Plasma exchange in neurology: a long experience of a safe procedure
Miguel Lozano, M.D., Ph.D., Clínic University Hospital, Barcelona, Spain

15 min AMBAR: A multi-mechanism approach for AD
Montserrat Costa, Ph.D., Grifols Bioscience Research Group, Spain

20 min AMBAR: primary results
Javier Olazarán, M.D., Gregorio Marañón University Hospital, Madrid, Spain

10 min Q&As. Discussion
All